Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly's study on P-tau217, a blood test for Alzheimer's disease, published in JAMA, demonstrates its superior ability to distinguish Alzheimer's from other neurodegenerative diseases when compared to current biomarkers and imaging methods. The test showed elevated levels in Colombian mutation carriers' blood, indicating Alzheimer's potential onset up to 20 years before symptoms. The findings support earlier diagnosis and better treatment strategies. However, the test is not yet approved and requires further validation. Lilly remains committed to advancing Alzheimer's research and diagnostics.

Eli Lilly and Company (NYSE: LLY) announced new findings from 17 studies to be presented at the virtual Alzheimer's Association International Conference (AAIC) 2020, from July 27-31. The research focuses on developing disease-modifying therapies for Alzheimer's and improving diagnostic methods. The company has emphasized its commitment to Alzheimer's research for over 30 years, highlighting the urgency of addressing this growing health crisis. Specific studies will cover topics such as blood biomarkers and Flortaucipir PET imaging, aiming to enhance diagnosis and treatment in Alzheimer's patients.

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on July 30, 2020. A conference call for investors and media will take place at 9 a.m. Eastern time on the same day. Participants can access the live webcast through a link on Lilly's website, with a replay available afterwards. Eli Lilly aims to enhance its global healthcare leadership by creating life-changing medicines and improving disease management.

Eli Lilly and Company (NYSE:LLY) announced positive results from the OASIS-2 study, demonstrating that mirikizumab, an investigational monoclonal antibody, met primary and key secondary endpoints against both placebo and Cosentyx at Weeks 16 and 52. At Week 16, the Static Physician's Global Assessment (sPGA) showed 79.7% improvement for mirikizumab versus 6.3% for placebo. Safety profiles remained consistent with previous findings. Lilly aims to bring mirikizumab to market as a potential treatment for moderate to severe plaque psoriasis, along with ongoing studies for inflammatory bowel diseases.

Eli Lilly and Company (NYSE: LLY) has declared a third-quarter dividend of $0.74 per share on its outstanding common stock. The dividend is scheduled for payment on September 10, 2020, to shareholders of record by the close of business on August 14, 2020. This dividend announcement reflects Lilly's commitment to returning value to its shareholders and maintaining robust financial health.

Eli Lilly has launched the Know Before the Low initiative to increase awareness and preparedness for low blood sugar emergencies among the 34 million Americans with diabetes. The program aims to educate individuals on recognizing symptoms and developing rescue plans with their support networks. Crystal Bowersox, a diabetes ambassador, emphasizes the importance of having a support system. Resources are available at KnowBeforeTheLow.com to help people understand low blood sugar signs and prepare effective emergency responses.

Boehringer Ingelheim and Eli Lilly announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials, evaluating Jardiance® (empagliflozin) in chronic heart failure patients. The trials showed no significant improvement in exercise ability with Jardiance compared to placebo, with median six-minute walk test increases of 13.5 meters and 10.0 meters for Jardiance against 18.0 and 5.0 meters for placebo, respectively. However, exploratory analyses indicated quality of life improvements. Safety profiles were consistent across diabetic and non-diabetic participants.

Eli Lilly's Emgality has shown significant results in reducing the total pain burden for patients with episodic and chronic migraine. In a recent study, patients using Emgality experienced an average of 68.6 fewer severity-weighted hours of pain per month for episodic migraine and 102.6 fewer hours for chronic migraine compared to baseline. This analysis was presented at major neurology conferences, marking Emgality as the first CGRP medication to be assessed on total pain burden, enhancing understanding of migraine management.

Eli Lilly and Company (NYSE: LLY) revealed that less than 30% of migraine sufferers are using recommended prescription medications, according to the OVERCOME study. The study, involving over 21,000 participants, aims to identify barriers in migraine treatment. Key findings showed that among individuals with significant migraine-related disability, 63% sought care, but only 28% completed all three critical steps (seeking care, receiving a diagnosis, and taking medication). The research highlights the ongoing challenges in migraine care, including stigma and accessibility issues.